Empagliflozin activates Wnt/β-catenin to stimulate FUNDC1-dependent mitochondrial quality surveillance against type-3 cardiorenal syndrome
Source : https://www.sciencedirect.com/science/article/pii/S2212877822001223?via=ihub
Empagliflozin reduces myocardial damage and improves myocardial function after CRS-3. * Empagliflozin normalizes the mitochondrial structure in cardiomyocytes during CRS-3. * Empagliflozin attenuates cardiomyocyte mitochondrial dysfunction during CRS-3. * Empagliflozin...
Conclusion: In summary, empagliflozin activated Wnt/β-catenin to stimulate FUNDC1-dependent mitochondrial quality surveillance, ultimately improving mitochondrial function and cardiac performance during CRS-3. Thus, empagliflozin could be considered for the clinical management of heart function following acute kidney injury.
Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy
Until 2021, medical treatment of patients with heart failure (HF) and preserved ejection fraction (HFpEF) was mainly limited to diuretics to improve symptoms of HF, while no therapies demonstrated a...
Conclusion: The authors describe the rationale for this therapy, presenting the main results of the EMPEROR-Preserved trial, and provide some recommendations for the everyday clinical management of HF with preserved left ventricular ejection with an SGLT2I.
Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35796209/
The combination of NT-proBNP and hs-cTnT along with a few readily available clinical variables provides effective risk discrimination both for morbidity and mortality in patients with HFpEF. A predictive toolkit...
Conclusions: The combination of NT-proBNP and hs-cTnT along with a few readily available clinical variables provides effective risk discrimination both for morbidity and mortality in patients with HFpEF. A predictive toolkit facilitates the ready implementation of these risk models in routine clinical practice.
Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction - American Journal of Cardiovascular Drugs
Source : https://link.springer.com/article/10.1007/s40256-022-00542-9
Background Clinical trials reported the benefit of empagliflozin when combined with standard treatment relative to cardiovascular death or heart failure (HF) hospitalization in patients with heart failure with reduced or...
Dapagliflozin and Empagliflozin in Heart Failure | IJGM
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including dapagliflozin and empagliflozin, are a new type of oral glucose-lowering drugs that can control blood glucose by inhibiting SGLT2 in the kidney. The DAPA-HF trial...
Conclusion: Despite its many limitations, this study suggested that different SGLT2 inhibitors might have differences regarding efficacy in HFrEF. We look forward to future studies to verify our conjectures.